The world’s first Ebola vaccine is finally approved, a critical move that opens the door for its use in countries at high risk for the infectious disease.
Interested in Ebola?
Add Ebola as an interest to stay up to date on the latest Ebola news, video, and analysis from ABC News.
Just 48 hours after the European Commission granted marketing authorization for the vaccine, the World Health Organization (WHO) announced Tuesday that it had also pre-qualified the vaccine, meaning it meets the WHO’s quality, safety and efficacy standards.
(MORE: Congolese journalist who helped raise awareness of Ebola killed in attack, officials say)
Tedros Adhanom Ghebreyesus, the WHO’s director-general, called the approval «a historic step» toward making sure people who need the vaccine most have access to it.
«Five years ago, we had no vaccine and no therapeutics for Ebola,» he said in a statement. «With a pre-qualified vaccine and experimental therapeutics, Ebola is now preventable and treatable.»
Junior Kannah/AFP/Getty Images, FILE
In this May 21, 2018, file photo, a nurse working with the World Health Organization (WHO) shows a bottle containing Ebola vaccine in the town of Mbandaka, Democratic Republic of Congo, during the launch of the Ebola vaccination campaign.
Ebola, which is spread through contact with blood or other bodily fluids from an infected person, is rare, but frequently fatal. Death rates among those who contract Ebola range from 25% to 90%, according to the World Health Organization.
The vaccine, known as Ervebo, which is manufactured by U.S. drug-maker Merck, is currently being used in a «compassionate use» capacity in the eastern Democratic Republic of Congo, the site of an ongoing Ebola outbreak. That outbreak is the second-largest, second-deadliest Ebola outbreak on record.
Baz Ratner/Reuters, FILE
In this Aug. 5, 2019, file photo, a health worker injects a man with Ebola vaccine in Goma, Democratic Republic of Congo.
Since August 2018, more than 3,000 people in DRC have tested positive for Ebola virus, according to Congolese health officials. More than 2,000 people have died from the disease during that time. Over the last year, more than 250,000 have been vaccinated against Ebola in the DRC, using the Merck vaccine.
(MORE: Ebola outbreak spreads to 3rd province in eastern Democratic Republic of Congo)
A second experimental vaccine, produced by Johnson & Johnson, which requires two doses, is expected to be deployed in the 2 million-person city of Goma soon, according to Congolese health officials.